[Pyridostigmine with aminopyridines in myasthenia gravis or Lambert-Eaton myasthenic syndrome]

Rodríguez B, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001463
Spanish
Original Title: Piridostigmina con aminopiridinas en miastenia gravis o síndrome miasténico de Lambert Eaton
Authors' recomendations: CONCLUSIONS No evidence was found on the use of pyridostigmine with aminopyridines (3,4-diaminopyridine or fampridine or amifampridine) for chronic symptomatic management of patients with myasthenia gravis or during a myasthenic crisis. Moderate-quality evidence suggests that there is no difference in terms of improvement in muscle strength two hours after combination treatment with intravenous pyridostigmine and 3,4-diaminopyridine when compared with 3,4-diaminopyridine alone in patients with Lambert-Eaton myasthenic syndrome. No clinical practice guidelines (CPG) on myasthenia gravis management recommend this combination treatment. The only CPG mentioning it for Lambert-Eaton patients, although it reports there may be some benefit with the combination, recommends adding immunosuppressors in patients not responding to monotherapy with aminopyridines. The health sponsors assessed either do not mention or do not cover the pyridostigmine with aminopyridines combination in any of the assessed indications.
Details
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Myasthenia Gravis
  • Lambert-Eaton Myasthenic Syndrome
  • Pyridostigmine Bromide
  • 4-Aminopyridine
  • Amifampridine
  • Drug Therapy, Combination
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.